Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics, Inc. (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation. In parallel, Jasper is advancing JN-6000, an extended-release formulation of tacrolimus aimed at reducing the toxicity and dosing complexities associated with conventional immunosuppressive regimens. The company is also investigating JN-403, a small-molecule agent intended to prevent and treat vaso-occlusive crises in sickle cell disease.

Since its founding, Jasper Therapeutics has established collaborations with leading academic institutions and biotechnology partners to support its clinical programs and expand its platform capabilities. The company is headquartered in Tarrytown, New York, and maintains research activities in key U.S. biotech hubs. Jasper’s leadership team brings together expertise in translational medicine, clinical development, and regulatory affairs to guide its efforts from early-stage discovery through pivotal studies.

With a strategic focus on leveraging immunological insights to design targeted therapies, Jasper Therapeutics aims to deliver novel treatment options for patients experiencing life-threatening disorders. Its ongoing clinical trials and preclinical initiatives reflect a commitment to advancing scientific innovation in areas where current therapeutic choices are limited.

Key Stats

• Today's Range: $0.76 to $0.88
• 50-Day Range: $0.34 to $0.96
• 52-Week Range: $0.32 to $3.31
• Volume: 1.71 million shs
• Average Volume: 3.11 million shs
• Market Capitalization: $21.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Jasper Therapeutics Stock Analysis - MarketRank™

Jasper Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 447th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Jasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Jasper Therapeutics has a consensus price target of $12.00, representing about 1,458.4% upside from its current price of $0.77.

Amount of Analyst Coverage

Jasper Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Jasper Therapeutics are expected to grow in the coming year, from ($1.67) to ($1.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jasper Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jasper Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jasper Therapeutics has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.23% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 13.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jasper Therapeutics does not currently pay a dividend.

Dividend Growth

Jasper Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.33

News Sentiment

Jasper Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Jasper Therapeutics this week, compared to 5 articles on an average week.

Search Interest

10 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

6 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.30% of the stock of Jasper Therapeutics is held by insiders.

Percentage Held by Institutions

79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/22/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JSPR
• CIK: 1788028
• Web: jaspertherapeutics.com
• Phone: 650-549-1400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jasper Therapeutics: $12.00
• High Price Target: $25.00
• Low Price Target: $3.00
• Potential Upside/Downside: +1,458.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -613.51%
• Return on Assets: -162.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.26
• Quick Ratio: 2.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 5.13

Miscellaneous

• Outstanding Shares: 28,000,000
• Free Float: 27,353,000
• Market Cap: $21.56 million
• Optionable: Optionable
• Beta: 3.07